Monitoring allows your provider to evaluate treatment response, review glucose metabolism, IGF-1 levels, medication tolerance, and determine whether therapy continues to support your health goals
We monitor patients and adjust protocols based on response
Three key findings result from our study: (1) pwIIH treated with GLP-1-RAs lose significantly more weight than pwIIH electing for UCWM only, (2) treatment with GLP-1-RAs is associated with favorable headache outcomes, and (3) treatment with GLP-1-RAs is not associated with any severe adverse events in IIH, and thus presents a safe treatment option for weight management in pwIIH
Lower /mg batching 10 vials cuts our fill cost, and we pass it to you (per-vial price is 4060% lower than typical single-vial pricing)
Although this study was not powered to assess these effects, sex was included as a covariate in all our analyses, and we did see a larger decrease in thalamic GABA levels in boys with migraine compared to girls with migraine
Nov 17 2021;13(11)doi:10.3390/nu13114126
